Bluejay Diagnostics (BJDX) Invested Capital (2020 - 2021)

Bluejay Diagnostics (BJDX) reported Invested Capital of $2000.0 for Q4 2021, down 98.4% on a YoY basis from $125102.0 in Q4 2020, and down 98.26% sequentially from $115102.0 in Q3 2021.

Bluejay Diagnostics (BJDX) Invested Capital (2020 - 2021) Analysis & Trends

Bluejay Diagnostics (BJDX) has 2 years of Invested Capital data on file, last reported at $2000.0 in Q4 2021.

  • For the quarter ending Q4 2021, Invested Capital fell 98.4% year-over-year to $2000.0; the trailing twelve-month figure through Sep 2022 stood at $2000.0 (down 99.17% YoY), and the FY2021 full-year result was $2000.0, down 98.4% from the prior year.
  • Invested Capital fell to $2000.0 in Q4 2021, from $115102.0 in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $125102.0 in Q4 2020 to a low of $2000.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 4.41 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 499.00 Mn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 1.79 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 41.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 1.41 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 7.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - 15.00 Mn
10 Bluejay Diagnostics 2,754.24 2,754.24 - -

Historic Data

Download Data
DateValue
Dec 31, 2021 2,000.00
Sep 30, 2021 115,102.00
Dec 31, 2020 125,102.00